The role of modulators in cystic fibrosis related diabetes

被引:26
|
作者
Merjaneh, Lina [1 ]
Hasan, Sana [2 ]
Kasim, Nader [3 ]
Ode, Katie Larson [4 ]
机构
[1] Seattle Childrens Hosp, Dept Pediat, Div Endocrinol, Seattle, WA USA
[2] Cleveland Clin Fdn, Dept Endocrinol & Metab, Cleveland, OH USA
[3] Helen Devos Childrens Hosp, Div Pediat Diabet & Endocrinol, Spectrum Hlth, Grand Rapids, MI USA
[4] Univ Iowa, Dept Pediat, Div Endocrinol, Stead Family Childrens Hosp, Iowa City, IA USA
关键词
CFRD; Modulator therapy; Insulin; INSULIN-SECRETION; TEZACAFTOR-IVACAFTOR; CHLORIDE CHANNEL; CFTR; EPIDEMIOLOGY; CHILDREN;
D O I
10.1016/j.jcte.2021.100286
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development and introduction of modulator therapies have completely shifted the paradigm for the treatment of cystic fibrosis (CF). Highly effective modulator therapies have driven marked improvements in lung function, exacerbation rate, weight and quality of life in CF patients. However, their effect on CF related diabetes (CFRD) is not well delineated. The role of CF transmembrane conductance regulator (CFTR) in CFRD pathogenesis is inadequately understood and research aimed at deciphering the underlying mechanisms of CFRD continues to evolve. In this review, we summarize what is known regarding the effect of CFTR modulators on CFRD. Small studies using ivacaftor monotherapy in gating mutations have revealed improvement in insulin secretion, glucose tolerance and/or decrease in insulin requirement. However, lumacaftor/ivacaftor studies (primarily in delta F 508 homozygous) have not revealed significant improvement in CFRD or glucose tolerance. No studies are yet available regarding the effect of the highly effective triple therapy (elexacaftor/tezacaftor/ivacaftor) on CFRD or insulin secretion. CFTR modulators might affect development or progression of CFRD through many mechanisms including improving insulin secretion by correcting the CFTR defect directly, improving ductal function, reducing islet inflammation, and improving incretin secretion or by enhancing insulin sensitivity via reduced systemic inflammation and increased physical activity driven by improved lung function and quality of life. On the other hand, they can stimulate appetite and improve gastrointestinal function resulting in increased caloric intake and absorption, driving excessive weight gain and potentially increased insulin resistance. If the defect in insulin secretion is reversible then it is possible that initiation of CFTR modulators at a younger age might help prevent CFRD. Despite the advances in CF management, CFRD remains a challenge and knowledge continues to evolve. Future studies will drive better understanding of the role of highly effective CFTR modulators in CFRD.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Unique challenges of cystic fibrosis-related diabetes
    Bridges, N.
    Rowe, R.
    Holt, R. I. G.
    DIABETIC MEDICINE, 2018, 35 (09) : 1181 - 1188
  • [22] Advances in the detection and management of cystic fibrosis related diabetes
    Hameed, Shihab
    Jaffe, Adam
    Verge, Charles F.
    CURRENT OPINION IN PEDIATRICS, 2015, 27 (04) : 525 - 533
  • [23] Cystic Fibrosis-Related Diabetes in Children: An Update
    Kim, Roy J.
    PEDIATRIC ANNALS, 2016, 45 (09): : E321 - E326
  • [24] Cystic Fibrosis Related Diabetes (CFRD)
    Mosnier-Pudar, Helen
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2017, 21 (9-10): : 237 - 240
  • [25] Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults
    Konrad, Katja
    Scheuing, Nicole
    Badenhoop, Klaus
    Borkenstein, Martin H.
    Gohlke, Bettina
    Schoefl, Christof
    Seufert, Jochen
    Thon, Angelika
    Holl, Reinhard W.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2013, 29 (07) : 568 - 575
  • [26] Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)
    de Noronha, Renata Maria
    Procopio Calliari, Luis Eduardo
    Damaceno, Neiva
    Muramatu, Lucia Harumi
    Monte, Osmar
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2011, 55 (08) : 613 - 621
  • [27] Advances in cystic fibrosis-related diabetes: Current status and future directions
    Lurquin, F.
    Buysschaert, M.
    Preumont, V.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (11)
  • [28] The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
    Sergeev, Valentine
    Chou, Frank Y.
    Lam, Grace Y.
    Hamilton, Christopher Michael
    Wilcox, Pearce G.
    Quon, Bradley S.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (02) : 147 - 154
  • [29] Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes
    Al-Selwi, Yara
    Shaw, James A. M.
    Kattner, Nicole
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2021, 14
  • [30] Increased detection of cystic-fibrosis-related diabetes in Australia
    Rana, Malay
    Munns, Craig F.
    Selvadurai, Hiran C.
    Simonds, Sharon
    Cooper, Peter J.
    Woodhead, Helen J.
    Hameed, Shihab
    Verge, Charles F.
    Lafferty, Antony R.
    Crock, Patricia A.
    Craig, Maria E.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2011, 96 (09) : 823 - U168